The DOI matches its Crossref record; the references it cites are not checked yet.
EDC Cross-linking of Decellularized Tissue: A Promising Approach?
Abstract
BACKGROUND: Decellularization of xenogenous cardiovascular structures is a promising approach to create scaffolds for tissue engineering. Unfortunately, handling and pliability of the unfixed tissue is challenging. N-(3-dimethylaminopropyl)-N9-ethylcarbodiimide (EDC) is an alternative cross-linking agent to glutaraldehyde (GA). Applied in native tissue, it provides biocompatibility and shows no potential for calcification. In addition, EDC can be used to link growth factors (GFs) to tissue scaffolds after decellularization. EDC cross-linking could thereby help to improve decellularized tissue without the toxicity of GA. MATERIAL AND METHODS: Porcine aortic wall tissue specimens (TS) were decellularized, treated with EDC, and coated with fibroblast growth factor (FGF) or vascular endothelial growth factor (VEGF). Afterward, TS were subcutaneously implanted in 36 Lewis rats along with one decellularized TS without EDC treatment. After 2, 4, and 6 weeks TS were explanted from 12 rats, respectively. Vital cells were evaluated by RNA quantification, general cellular infiltration by hematoxylin and eosin staining (H&E), macrophage infiltration by CD68 staining, calcification by Von-Kossa staining, and tissue degradation by measurement of TS thickness. RESULTS: Quantification of vital cells showed reduced reseeding of EDC-treated TS compared to noncross-linked TS after 2 (p < 0.05) and 4 weeks (p < 0.05), while after 6 weeks only EDC+VEGF showed fewer viable cells (p < 0.01). Histological evaluation confirmed a reduced infiltration of EDC-treated TS. Macrophage infiltration decreased in all groups from 2 to 6 weeks, with the smallest population in EDC+VEGF-treated TS (p > 0.05). In EDC+FGF-treated TS, macrophages were reduced after 2 weeks compared to noncross-linked TS (p < 0.05), while after 4 and 6 weeks no significant difference was found (p > 0.05). Von-Kossa staining revealed no calcification in any of the specimens. Thickness of noncross-linked and EDC+FGF-treated TS was not different at the respective times of explantation, but decreased in both groups toward 6 weeks. CONCLUSION: EDC cross-linking combined with GF coating of decellularized aortic wall tissue showed encouraging results. The treatment did not impair the advantages of decellularized tissue such as long-term recellularization, absence of calcification, and tissue integrity. Based on the low macrophage infiltration and minimal tissue degradation, treatment with EDC and VEGF could be useful after decellularization. However, further research is necessary to verify these findings in models, including mechanical stress.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“genipin19 and carbodiimide20 have also been utilized as biocompatible crosslinking agents, but achieving high effectiveness comparable to the effectiveness of GA remains unresolved.”
From Bioengineered liver crosslinked with nano-graphene oxide enables efficient liver regeneration via MMP suppression and immunomodulation (2023) · cites this paper as [20]
Citations
The citation lists haven’t been fetched yet
References 37 · Cited by 30
Research works printed but not linked: 35
- 10.1089/ten.2006.12.2059 · DOI
- 10.12659/MSM.883618 · DOI
- 10.1089/ten.tea.2011.0046 · DOI
- Dohmen P.M., 2007, J Heart Valve Dis, 16, 447
- 10.1159/000091597 · DOI
- 10.1016/j.athoracsur.2004.06.033 · DOI
- Golomb G., 1987, Am J Pathol, 127, 122
- Grabenwöger M., 1996, Surg, 62, 772
- 10.1016/0142-9612(96)82721-9 · DOI
- Curcio C.A., 1981, J Thorac Cardiovasc Surg, 81, 621, 10.1016/S0022-5223(19)39497-8 · DOI
- 10.1093/rb/rbu009 · DOI · Paper page
- 10.1016/0003-2697(90)90267-D · DOI
- 10.1016/0142-9612(96)81413-X · DOI
- 10.1016/S0939-6411(98)00017-4 · DOI
- 10.1089/ten.2006.0292 · DOI
- Xu X.-F., 2014, Int J Clin Exp Med, 7, 649
- 10.5090/kjtcs.2013.46.1.1 · DOI
- 10.1016/S0142-9612(00)00164-2 · DOI
- 10.1002/jbm.b.31928 · DOI
- 10.1111/j.1525-1594.2009.00713.x · DOI
- 10.1002/1097-4636(20010605)55:3<368::AID-JBM1025>3.0.CO;2-5 · DOI
- 10.1016/S0168-3659(99)00145-5 · DOI
- 10.1016/S0142-9612(00)00418-X · DOI
- 10.1111/j.1525-1594.2004.00062.x · DOI
- 10.1042/BSR20110077 · DOI
- 10.4061/2010/218142 · DOI
- 10.1152/ajpcell.2001.280.6.C1358 · DOI
- Distler J.H.W., 2003, Q J Nucl Med, 47, 149
- 10.1002/(SICI)1097-4636(19990605)45:3<209::AID-JBM8>3.0.CO;2-N · DOI
- Xu X.-F., 2013, Int J Clin Exp Med, 6, 524
- 10.1016/j.trim.2003.12.016 · DOI · Paper page
- 10.1016/j.biomaterials.2006.08.022 · DOI
- 10.1038/nri1733 · DOI · Paper page
- Grabenwöger M., 1992, J Thorac Cardiovasc Surg, 104, 14, 10.1016/S0022-5223(19)34831-7 · DOI
- 10.12659/MSMBR.893088 · DOI
Metadata
- Authors
- Lehmann, N., Christ, T., Daugs, A., Bloch, O., & Holinski, S.
- Affiliations
- Department of Research and Development, AutoTissue Berlin GmbH, Berlin, Germany.
- Charité – Universitätsmedizin Berlin (DE)
- Corresponding author
- Christ, Torsten
- Venue
- Tissue Engineering Part A
- Publisher
- SAGE Publications
- Published
- 2017-07
- Volume
- 23
- Issue
- 13-14
- Pages
- 675-682
- ISSN
- 1937-3341 (ISSN-L)
- 1937-335X
- OpenAlex
- W2607629280
- Cited by
- 30
- References
- 37
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 6 · 2023: 5 · 2022: 4 · 2021: 4 · 2020: 4 · 2019: 1 · 2018: 1
- FWCI
- 1.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Tissue Engineering Part A (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Physical Sciences › Engineering › Biomedical Engineering › Bone Tissue Engineering Materials
- Keywords
- decellularized tissue, EDC crosslinking, glutaraldehyde alternative, tissue engineering scaffolds, macrophage infiltration, calcification, reseeding, tissue degradation, xenotransplantation, Lewis rats, tissue engineering, biocompatibility, growth factor delivery
- MeSH terms
- Animals, Carbodiimides, Cross-Linking Reagents, Fibroblast Growth Factors, Materials Testing, Rats, Inbred Lew, Swine, Coated Materials, Biocompatible, Vascular Endothelial Growth Factor A, Rats, Tissue Scaffolds
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: EDC Cross-linking of Decellularized Tissue: A Promising Approach? https://app.cochat.ai/papers/10.1089/ten.tea.2016.0416
- The paper
- Lehmann, N., Christ, T., Daugs, A., Bloch, O., & Holinski, S. (2017). EDC Cross-linking of Decellularized Tissue: A Promising Approach? Tissue Engineering Part A. https://doi.org/10.1089/ten.tea.2016.0416